Search

Displaying results 2921 - 2930 of 4335 in total
  1. Drug

    Oseltamivir

    go.drugbank.com/drugs/DB00198
    ApprovedInvestigational

    Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. … 48 hours of the onset of influenza symptoms since effectiveness decreases significantly after that point in time; there is generally no benefit in use beyond 48 hours for healthy, low-risk individuals as

  2. Drug

    Anecortave acetate

    go.drugbank.com/drugs/DB05288
    Investigational

    As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.

  3. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals. Betahistine is a histamine...

    Products: BETAISTINA MYLAN GENERICS, BETAISTINA DOC GENERICI
  4. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting

  5. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    many as 40% of patients will experience relapsed or refractory disease. … ,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies - such as

  6. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as voxilaprevir. … Voxilaprevir has been available since July 2017 in a fixed dose combination product with [sofosbuvir] and [velpatasvir] as the commercially available product Vosevi.

  7. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection … Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by

  8. Drug

    Alanine

    go.drugbank.com/drugs/DB00160
    ApprovedInvestigationalNutraceutical

    Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle...

  9. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV. Its target is similar to that of fluoroquinolone antibacterials - e.g. ciprofloxacin - while being structurally and p...

  10. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol...